ABSTRACT
Rheumatic diseases are among the most common chronic inflammatory disorders. Besides severe pain and progressive destruction of the joints, rheumatoid arthritis (RA), spondyloarthritides (SpA) and psoriatic arthritis (PsA) impair working ability, reduce quality of life and if treated insufficiently may enhance mortality. With the introduction of biologics to treat these diseases, the demand for biomarkers of early diagnosis and therapeutic stratification has been growing continuously. The main goal of the consortium ArthroMark is to identify new biomarkers and to apply modern imaging technologies for diagnosis, follow-up assessment and stratification of patients with RA, SpA and PsA. With the development of new biomarkers for these diseases, the ArthroMark project contributes to research in chronic diseases of the musculoskeletal system. The cooperation between different national centers will utilize site-specific resources, such as biobanks and clinical studies for sharing and gainful networking of individual core areas in biomarker analysis. Joint data management and harmonization of data assessment as well as best practice characterization of patients with new imaging technologies will optimize quality of marker validation.
Subject(s)
Arthritis, Psoriatic/diagnosis , Arthritis, Rheumatoid/diagnosis , Biomarkers/blood , Early Diagnosis , Spondylarthritis/diagnosis , Arthritis, Psoriatic/blood , Arthritis, Psoriatic/classification , Arthritis, Psoriatic/genetics , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/classification , Arthritis, Rheumatoid/genetics , Autoantibodies/blood , Diagnostic Imaging , Disability Evaluation , Genotype , Humans , Interdisciplinary Communication , Intersectoral Collaboration , Quality of Life , Spondylarthritis/blood , Spondylarthritis/classification , Spondylarthritis/geneticsABSTRACT
Development of the recently described Th9 cells is selectively and dynamically controlled by epigenetic modifications. The selective epigenetic inactivation of the PU.1 promoter associated with diminished Th9 cell differentiation by naive CD4 T cells allows the assumption of a special physiologic role of IL-9. Once deregulated, IL-9 seems to play an important role in the pathogenesis of several autoimmune disorders.
Subject(s)
Autoimmune Diseases/immunology , Cytokines/immunology , Epigenesis, Genetic/immunology , Interleukin-9/immunology , Models, Immunological , T-Lymphocytes, Helper-Inducer/immunology , Animals , HumansABSTRACT
The introduction of biologics has continuously increased the demand for biomarkers for early diagnosis and therapeutic stratification. ArthroMark, a research network funded by the Federal Ministry of Education and Research, aims to establish such biomarkers for rheumatoid arthritis and spondyloarthritides. Biobanks and previous work on genotyping, gene expression and autoreactivity profiling build the basis. Bioinformatic networks will help to harmonize the investigations and a clinical study with modern imaging techniques to characterize the functional relevance of the new biomarkers as effectively as possible. To validate the markers for diagnostic application the network aims to expand gradually.
Subject(s)
Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/diagnosis , Biomarkers/blood , Practice Guidelines as Topic , Rheumatology/standards , Spondylarthritis/blood , Spondylarthritis/diagnosis , Germany , HumansABSTRACT
CD4 T cells play a major role in the development and persistence of autoimmune rheumatic diseases. The recent identification of IL-17-producing Th17 cells as a potent proinflammatory subset extends the understanding of pathophysiological processes not explained by the Th1/Th2 dichotomy. The recent data from human studies discussed in this article indicate an important pathogenic function for Th17 cells and Th17-derived IL-17 suggesting that therapies targeting Th17 cells/IL-17 may be of potential use in the treatment of those diseases.
Subject(s)
Autoimmune Diseases/immunology , Interleukin-17/immunology , Models, Immunological , Rheumatic Diseases/immunology , T-Lymphocytes/classification , T-Lymphocytes/immunology , Autoimmune Diseases/pathology , Humans , Rheumatic Diseases/pathologyABSTRACT
In addition to natural thymus-derived regulatory T-cells (Tregs), peripherally-induced Tregs are of central importance in immune homeostasis. Homotypic interactions between activated effector T-cells and resting memory T-cells induced the generation of IL-10 and IFNgamma producing Tregs in vitro. This mechanism in Treg development allows new insights into T-cell vaccination, which has been employed in pilot trials of multiple sclerosis and rheumatoid arthritis with promising results.
Subject(s)
Autoimmune Diseases/pathology , Autoimmune Diseases/surgery , T-Lymphocytes, Regulatory/transplantation , HumansABSTRACT
OBJECTIVE: To investigate whether MHC class II expression on myeloid cells of patients with treatment-naive early rheumatoid arthritis (RA) correlates with disease progression. METHODS: Monocytes were isolated by negative selection from the peripheral blood of 15 patients with early RA (disease duration < or =12 months), differentiated to macrophages and analysed for MHC class II expression by flowcytometry. The phenotypical data were correlated with clinical disease progression for up to 45 months. RESULTS: Before treatment was initiated, in vitro differentiated macrophages of 10/15 early RA patients expressed MHC class II comparable with macrophages from healthy controls. In sharp contrast, macrophages of the remaining five patients expressed significantly fewer MHC class II molecules. In contrast to patients with normal levels of myeloid cell MHC class II expression, who developed a smouldering, non-progressive disease, patients with decreased expression of MHC class II on macrophages early in their disease developed a continuously active disease as demonstrated by persistently increased disease activity scores (chi(2) = 4.54, P < 0.02) and progressive bone destructions (chi(2) = 5.66, P < 0.02) despite aggressive therapy. CONCLUSION: The level of myeloid cell MHC class II expression in recent onset RA allows a reliable distinction between patients who develop active and destructive RA and patients with a smouldering, slowly progressive disease.
Subject(s)
Arthritis, Rheumatoid/blood , HLA-DR Antigens/blood , Myeloid Cells/metabolism , Adult , Aged , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biomarkers/blood , Cell Differentiation , Cells, Cultured , Disease Progression , Female , Follow-Up Studies , Humans , Macrophages/metabolism , Male , Middle Aged , Monocytes/metabolism , Pilot Projects , Prognosis , Severity of Illness Index , Treatment OutcomeABSTRACT
Rheumatic inflammation is driven by sustained specific immunity against self-antigens, resulting in local inflammation and cellular infiltration and, subsequently, in tissue damage. Although the specific autoantigen(s) eliciting the detrimental immune reactions in rheumatic diseases have rarely been defined, it has become clear that the mechanisms resulting in the destruction of tissue and the loss of organ function during the course of the diseases are essentially the same as in protective immunity against invasive microorganisms. Of fundamental importance in initiating, controlling, and driving these specific immune responses are CD4 T cells. Currently available data provide compelling evidence for a major role of CD4 T cells in the initiation and perpetuation of chronic rheumatic inflammation. Consequently, T cell-directed therapies have been employed with substantial clinical success in the treatment of rheumatic diseases. Here, we review current knowledge based on which CD4 T cells can be implicated as the motor of rheumatic inflammation.
Subject(s)
Arthritis, Rheumatoid/immunology , Lymphocyte Activation , T-Lymphocytes/immunology , Animals , Arthritis, Rheumatoid/etiology , Arthritis, Rheumatoid/therapy , CD4-Positive T-Lymphocytes/immunology , Humans , T-Lymphocyte Subsets/immunology , Th1 Cells/immunology , Th2 Cells/immunologyABSTRACT
Immense progress has been made in recent years in the management of patients with autoimmune diseases, such as rheumatoid arthritis (RA). This progress is largely owed to the advances in our understanding of cellular and molecular mechanisms involved in the pathogenesis of inflammation and autoimmunity and the substantially improved knowledge of molecular biology. In this editorial review, we delineate recent developments in the treatment of RA with a focus on biological therapeutics. we outline the concerns and open questions risen by the current studies and we portray future expectations based on the recent observations from those trials with biological treatment interventions.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/physiopathology , Humans , ImmunotherapyABSTRACT
To delineate the molecular mechanisms regulating Th2 cell differentiation, CD28-mediated generation of Th2 effectors was analyzed. In the absence of TCR ligation CD28 stimulation induced Th2 differentiation of memory but not of naive CD4(+) T cells, whereas costimulation via CD28 and the TCR enhanced Th2 differentiation from naive T cells but suppressed it from memory T cells. Stimulation of T cells via the CD28 pathway, therefore, provided critical signals facilitating Th2 cell differentiation. By comparing the responses to CD28 stimulation in memory and naive T cells and by using specific inhibitors, signaling pathways were defined that contributed to Th2 differentiation. CD28-induced Th2 differentiation required IL-4 stimulation and the activation of the mitogen-activated protein kinases p38 and extracellular signal-regulated kinases 1/2. CD28 engagement directly initiated IL-4 gene transcription in memory T cells and induced activation of phosphatidylinositol 3-kinase, p38, and c-Jun NH(2)-terminal kinase/stress-activated protein kinase pathways. Extracellular signal-regulated kinase phosphorylation that was necessary for Th2 differentiation, however, required stimulation by IL-2. These results indicate that optimal TCR-independent generation of Th2 effectors requires coordinate signaling via the CD28 and IL-2 pathways. TCR-independent generation of Th2 effectors might provide a mechanism to control Th1-dominated cellular inflammation.
Subject(s)
CD28 Antigens/physiology , Gene Expression Regulation/immunology , Interleukin-4/biosynthesis , Interleukin-4/genetics , Mitogen-Activated Protein Kinases/metabolism , Protein Serine-Threonine Kinases , Th2 Cells/cytology , Th2 Cells/enzymology , Adult , Antibodies, Monoclonal/pharmacology , Antigens, CD/metabolism , Antigens, CD/physiology , B7-1 Antigen/metabolism , B7-1 Antigen/physiology , B7-2 Antigen , CD28 Antigens/immunology , CD28 Antigens/metabolism , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/enzymology , CD4-Positive T-Lymphocytes/immunology , Cell Differentiation/immunology , Cells, Cultured , Drug Synergism , Enzyme Activation/immunology , Fetal Blood , Humans , Immunologic Memory/genetics , Interleukin-4/physiology , Interphase/genetics , Interphase/immunology , Jurkat Cells , Ligands , Membrane Glycoproteins/metabolism , Membrane Glycoproteins/physiology , Mitogen-Activated Protein Kinases/physiology , Phosphorylation , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Signal Transduction/immunology , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Th2 Cells/immunology , Transcription, Genetic/immunology , Tyrosine/metabolism , p38 Mitogen-Activated Protein KinasesABSTRACT
The chronic immune response in rheumatoid arthritis (RA) might be driven by activated Th1 cells without sufficient Th2 cell differentiation to down-modulate inflammation. To test whether disordered memory T cell differentiation contributes to the typical Th1-dominated chronic inflammation in RA we investigated differentiation of resting CD4+ memory T cells in patients with early (6 wk to 12 mo) untreated RA and in age- and sex-matched healthy controls in vitro. No difference in cytokine secretion profiles of freshly isolated memory T cells was detected between patients and controls. A cell culture system was then employed that permitted the differentiation of Th effectors from resting memory T cells by short term priming. Marked differences were found in response to priming. Th2 cells could be induced in all healthy controls by priming with anti-CD28 in the absence of TCR ligation. By contrast, priming under those conditions resulted in Th2 differentiation in only 9 of 24 RA patients. Exogenous IL-4 could overcome the apparent Th2 differentiation defect in seven patients but was without effect in the remaining eight patients. In all patients a marked decrease in IL-2-producing cells and a significant increase in well-differentiated Th1 cells that produced IFN-gamma but not IL-2 were evident after priming with anti-CD3 and anti-CD28. The data suggest that CD4+ memory T cells from patients with early untreated RA manifest an intrinsic abnormality in their ability to differentiate into specific cytokine-producing effector cells that might contribute to the characteristic Th1-dominated chronic (auto)immune inflammation in RA.
Subject(s)
Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/pathology , Immunologic Memory , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Adult , Aged , Arthritis, Rheumatoid/metabolism , CD4-Positive T-Lymphocytes/metabolism , Cell Differentiation/immunology , Chronic Disease , Cytokines/biosynthesis , Female , Humans , Lymphocyte Activation , Male , Middle Aged , Phosphorylation , STAT6 Transcription Factor , Signal Transduction/immunology , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/immunology , Th2 Cells/metabolism , Th2 Cells/pathology , Trans-Activators/biosynthesis , Trans-Activators/metabolismABSTRACT
Cyclic ADP-ribose (cADPR) is a natural compound that mobilizes calcium ions in several eukaryotic cells. Although it can lead to the release of calcium ions in T lymphocytes, it has not been firmly established as a second messenger in these cells. Here, using high-performance liquid chromatography analysis, we show that stimulation of the T-cell receptor/CD3 (TCR/CD3) complex results in activation of a soluble ADP-ribosyl cyclase and a sustained increase in intracellular levels of cADPR. There is a causal relation between increased cADPR concentrations, sustained calcium signalling and activation of T cells, as shown by inhibition of TCR/CD3-stimulated calcium signalling, cell proliferation and expression of the early- and late-activation markers CD25 and HLA-DR by using cADPR antagonists. The molecular target for cADPR, the type-3 ryanodine receptor/calcium channel, is expressed in T cells. Increased cADPR significantly and specifically stimulates the apparent association of [3H]ryanodine with the type-3 ryanodine receptor, indicating a direct modulatory effect of cADPR on channel opening. Thus we show the presence, causal relation and biological significance of the major constituents of the cADPR/calcium-signalling pathway in human T cells.